Evidence map›Paper›PMID 21539315›Full record

ArticleJournal of natural products2011

Antineoplastic agents. 590. X-ray crystal structure of dolastatin 16 and syntheses of the dolamethylleuine and dolaphenvaline units.

George R Pettit, Thomas H Smith, Jun-Ping Xu, Delbert L Herald, Erik J Flahive, Collin R Anderson, Paul E Belcher, John C Knight

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of natural products, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

George R PettitCancer Research Institute and Department of Chemistry and Biochemistry, Arizona State University, PO Box 871604, Tempe, Arizona 85287-1604, United States. bpettit@asu.edu
Thomas H Smith
Jun-Ping Xu
Delbert L Herald
Erik J Flahive
Collin R Anderson
Paul E Belcher
John C Knight

Funding

Molecular Target Focused Discovery of Anticancer DrugsR01CA090441 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI PETTIT, GEORGE R · 2001 to 2010
$4.8M
Molecular Target Focused Discovery of Anticancer DrugsR56CA090441 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI PETTIT, GEORGE R · 2007 to 2007
$498k
NCI NIH HHS 2R56-CA 090441-06A1NCI NIH HHS 5R01 CA 090441-07NCI NIH HHS R01 CA090441NCI NIH HHS R01 CA 90441-02-05NCI NIH HHS R56 CA090441
6 · The paper itself

Abstract

Three advances necessary to bring dolastatin 16 (1) into full-scale preclinical development as an anticancer drug have been accomplished. The X-ray crystal structure of dolastatin 16 has been solved, which allowed stereoselective syntheses of its two new amino acid units, dolamethylleuine (Dml) and dolaphenvaline (Dpv), to be completed. The X-ray crystal structures of synthetic Z-Dml and TFA-Dpv have also been completed.

Indexed as

Antineoplastic AgentsDepsipeptidesCrystallography, X-RayMolecular StructureAntineoplastic AgentsDepsipeptidesdolastatin 16

Identifiers

PMID21539315
PMCPMC3111978

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.